https://www.selleckchem.com/Bcl-2.html
To compare the relative efficacy and safety of pharmacological anti-inflammatory interventions for gout flares. We searched Ovid Medline, Embase and Cochrane library for randomized controlled trials (RCTs) that compared pharmacological anti-inflammatory treatment of gout flares. We conducted a network meta-analysis (NMA) using a frequentist framework, and assessed the certainty of evidence and made conclusions using the GRADE for NMA. In the 30 eligible RCTs, canakinumab provided the highest pain reduction at day two and at longest follow-up (Mean
Aimer
Commentaire
Partagez
